Skip to main content

Stratec Stock Forecast, Price & News

+1.40 (+1.27 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume7,758 shs
Average Volume6,253 shs
Market Capitalization$1.35 billion
P/E Ratio39.58
Dividend Yield0.82%
30 days | 90 days | 365 days | Advanced Chart
Receive SBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Stratec and its competitors with MarketBeat's FREE daily newsletter.

Stratec logo

About Stratec

Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.


See More Headlines

Industry, Sector and Symbol

Industry Medical Devices
Year FoundedN/A

Sales & Book Value

Annual Sales$265.59 million
Cash Flow€3.93 per share
Book Value€15.11 per share





Market Cap$1.35 billion
Next Earnings Date8/6/2021 (Estimated)


Overall MarketRank

1.30 out of 5 stars

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Stratec (ETR:SBS) Frequently Asked Questions

Is Stratec a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stratec in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stratec stock.
View analyst ratings for Stratec
or view top-rated stocks.

What stocks does MarketBeat like better than Stratec?

Wall Street analysts have given Stratec a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stratec wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Stratec's next earnings date?

Stratec is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Stratec

How has Stratec's stock price been impacted by Coronavirus (COVID-19)?

Stratec's stock was trading at €64.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBS shares have increased by 74.7% and is now trading at €111.80.
View which stocks have been most impacted by COVID-19

Is Stratec a good dividend stock?

Stratec pays an annual dividend of €0.90 per share and currently has a dividend yield of 0.82%. The dividend payout ratio of Stratec is 31.86%. This payout ratio is at a healthy, sustainable level, below 75%.
View Stratec's dividend history.

What price target have analysts set for SBS?

4 analysts have issued 12 month target prices for Stratec's stock. Their forecasts range from €112.00 to €151.00. On average, they expect Stratec's stock price to reach €130.50 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Stratec
or view top-rated stocks among Wall Street analysts.

Who are Stratec's key executives?

Stratec's management team includes the following people:
  • Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 54, Pay $707k)
  • Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 54, Pay $566k)
  • Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 54, Pay $484k)
  • Mr. Hermann Leistner, Founder & Advisor (Age 75)
  • Mr. Jan Keppeler, Head of Investor Relations & Corp. Communications
  • Mr. Andre Loy, Director of Corp. Communications
  • Mr. Roland Utz, Head of Supply Chain Management & Sr. VP

Who are some of Stratec's key competitors?

What other stocks do shareholders of Stratec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), 186808 (CHC), Bio-Rad Laboratories (BIO), Berkshire Hills Bancorp (BHLB), ASGN (ASGN), Apptio (APTI) and Anadarko Petroleum (APC).

What is Stratec's stock symbol?

Stratec trades on the ETR under the ticker symbol "SBS."

What is Stratec's stock price today?

One share of SBS stock can currently be purchased for approximately €111.80.

How much money does Stratec make?

Stratec has a market capitalization of $1.35 billion and generates $265.59 million in revenue each year.

How many employees does Stratec have?

Stratec employs 1,223 workers across the globe.

What is Stratec's official website?

The official website for Stratec is

Where are Stratec's headquarters?

Stratec is headquartered at Gewerbestr. 37, BIRKENFELD, 75217, Germany.

How can I contact Stratec?

Stratec's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.